# A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

Source: https://onco.cc/trials/nct02489318/  
OnCo record `nct02489318` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Apalutamide in prostate cancer, run by Aragon Pharmaceuticals, Inc., active and no longer recruiting.

## Summary

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC is a phase 3 interventional study registered as NCT02489318 by Aragon Pharmaceuticals, Inc., with 1052 participants enrolled, started 2015-11-27 and due to reach its primary completion in 2020-09-07. Interventions recorded: Apalutamide, Placebo, Androgen Deprivation Therapy (ADT). Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT02489318
- Phase: 3
- Setting: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Sponsor: Aragon Pharmaceuticals, Inc.
- Enrolled: 1052

## Sources

- ClinicalTrials.gov NCT02489318: https://clinicaltrials.gov/study/NCT02489318

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Apalutamide](https://onco.cc/drugs/apalutamide/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct02489318.json